Peptide Research in Europe

Published September 2026 · Patriot Labs Research Team · ~16 min read

The short answer

If you have read anything at all about research peptides, you have read European science — usually without being told so. The compound the market calls BPC-157 was characterized at the University of Zagreb School of Medicine in Croatia and has been studied there, almost continuously, since the early 1990s. The only multicentre randomized study of thymosin β4 ever run was conducted across ten clinical sites in Italy and Poland. And the technical rules that decide what a synthetic peptide has to be shown to be — how it is made, what impurities have to be characterized, what a specification must contain — are written by the European Medicines Agency in Amsterdam and the European Directorate for the Quality of Medicines in Strasbourg.

That last point is the one most often missed. Europe’s contribution to this field is not only the discovery record; it is the measurement record. A continent that has been holding a peptide symposium every two years since 1958 has spent a long time arguing about how you prove a peptide is what the label says. For anyone evaluating research-grade material, that argument is more useful than any individual study.

This guide walks through the European research behind the two peptides the market talks about most, the older European tradition they sit inside, the regulatory architecture that surrounds them, and — in a dedicated section, because it matters more than the rest — the specific things this literature does not establish.

Where peptide chemistry grew up

Peptide chemistry became a discipline in Europe before it became an industry anywhere. The first European Peptide Symposium was held in 1958, and the meeting has run biennially ever since; the European Peptide Society was formally constituted in 1989 to organise what had until then been an informal community of researchers meeting at those symposia. Its stated purpose is the promotion and advancement of research and training in the peptide sciences, and its published proceedings volumes are, in effect, a running record of how the field’s methods changed decade by decade.

That institutional continuity matters for a practical reason. Solid-phase peptide synthesis — the technique that makes essentially every synthetic peptide on the market, described in more detail in how peptides are made — arrived in the early 1960s and had to be validated, argued over and standardised before it could be trusted for anything regulated. A large part of that work happened in European laboratories and was reported at those symposia.

BPC-157 and the Zagreb school

BPC-157 is the clearest example of a European research programme that the wider world discovered thirty years late.

The molecule is a fifteen-residue peptide with the sequence GEPPPGKPADDAGLV and a molecular weight of roughly 1,419 Da. In the Zagreb literature it is described not as a designed drug but as a partial sequence of a larger protein found in human gastric juice — the “body protection compound” that gives the peptide its initials. The research group, led by Predrag Sikirić at the University of Zagreb School of Medicine, began publishing on it in the early 1990s.

The analytical property that the group has consistently placed at the centre of the work is stability. Their 2025 review states that the peptide is “always…stable in human gastric juice for more than 24 h,” and contrasts this directly with conventional peptidergic growth factors such as EGF and TGF-α, which are “rapidly degraded within minutes in gastric juice.” Whatever one concludes about the biology, this is a chemistry claim, and it is the reason the compound was pursued at all: a peptide that survives gastric conditions is a different experimental proposition from one that does not.

The mechanistic work has centred on angiogenesis and the nitric oxide system. The group’s framing is that the peptide “controls angiogenesis and the NO-system’s healing functions,” modulating rather than simply stimulating them. Downstream signalling described in that literature includes VEGFR2 and endothelial nitric oxide synthase.

The volume is genuinely unusual for a compound with no marketing authorisation. Press coverage in 2026, reporting on the Zagreb group, put the output at more than 150 published papers and over 100 completed doctorates on the topic, with roughly thirty papers reporting activity published by independent groups outside Croatia.

What the BPC-157 record contains — and what it does not

A 150-paper literature sounds decisive until you look at its shape. Two features define it.

It is overwhelmingly preclinical. The great majority of the work is animal — predominantly rodent — and much of it originates from a single institution. Independent replication outside Croatia exists but is a small fraction of the total. In evidence terms, a large body of work from one group is not equivalent to a comparable body of work from many.

The human record is close to empty. The Croatian pharmaceutical company Pliva ran a small phase 1/2 study in ulcerative colitis in the early 2000s. Its results were never fully published, and no phase 3 programme followed. A March 2026 review characterised the human trial evidence as very limited, with small sample sizes. There is no EMA marketing authorisation for BPC-157 and no national approval in any EU member state.

Thymosin β4, TB-500 and Europe’s one multicentre trial

The TB-500 story requires a distinction the market routinely collapses. Thymosin β4 is a 43-residue endogenous peptide. TB-500, as sold as a research material, is a short synthetic fragment associated with the actin-binding region of that parent molecule. They are not the same chemical entity, and a study of one is not a study of the other — a point developed further in BPC-157 vs TB-500.

That distinction is what makes the European trial worth knowing about precisely. In 2007, Giorgio Guarnera, Alfonso De Rosa and Roberto Camerini described, in the Annals of the New York Academy of Sciences, a double-blind, placebo-controlled, dose-escalation study of topically administered thymosin β4 in patients with venous ulcers. The design is worth stating in full because it is the most substantial piece of European clinical work on this molecule:

• Ten sites — five in Italy, five in Poland.
• Three sequential groups, 24 patients each, randomized 3:1 to thymosin β4 or placebo, with the dose escalating group by group once safety data showed no dose-limiting adverse events.
• 72 patients in total, treated for 84 days and followed for a further 14 days.
• Plasma thymosin β4 measured at day 0 and end of treatment; weekly clinical chemistry, haematology, coagulation and urinalysis.
• Ulcer area assessed by digital planimetry and photographic analysis; stated endpoints were the proportion of patients with complete closure of the index ulcer at day 84 and mean time to complete healing.

Note what that paper is and is not. It is a description of a study in progress — at the time of writing, 21 patients had been enrolled in the first, lowest-dose group. It reports design, conduct and operational lessons, not outcomes. Anyone citing it as evidence of an effect is citing a protocol description.

European work on the full-length peptide continued in laboratory settings, particularly in Italian groups studying thymosin β4 in tissue repair and cellular autophagy, and the International Symposium on Thymosins in Health and Disease series has run for decades. But the clinical record in Europe remains thin, and it concerns the 43-residue molecule rather than the fragment.

Four European peptides that became medicines

The contrast that puts BPC-157 and TB-500 in perspective is with European peptides that completed the journey the research market skips.

Desmopressin came out of the Institute of Organic Chemistry and Biochemistry in Prague, where Milan Zaoral’s group worked on vasopressin analogues with high and specific antidiuretic activity. It is a case study in what analogue design is for: a small, deliberate set of structural changes to an endogenous hormone to separate one activity from another.

Octreotide was developed at Sandoz in Basel in the early 1980s as a somatostatin analogue — the practical answer to the problem that native somatostatin has a half-life measured in minutes.

Hexarelin is an Italian-origin growth hormone secretagogue, a GHRP-6 analogue studied in human dose-response work from the mid-1990s onward, and part of the lineage that runs to the ghrelin-receptor peptides the market knows as ipamorelin and its relatives.

Liraglutide and semaglutide were developed at Novo Nordisk in Denmark, with Lotte Bjerre Knudsen a central figure in the acylation chemistry that turned a peptide with a few minutes of circulating life into one dosed weekly. The GLP-1 class is the single largest reason peptide manufacturing capacity is being built out across Europe today.

Each of these went through the full sequence: characterisation, analogue optimisation, controlled trials, regulatory review, and a pharmacopoeial monograph. Neither BPC-157 nor TB-500 has.

The rulebook: EMA, Ph. Eur. and the EDQM

This is the part of the European contribution that is most directly useful when evaluating research material, because it defines what “characterized” actually means.

In December 2025 the European Medicines Agency adopted a dedicated Guideline on the development and manufacture of synthetic peptides (EMA/CHMP/CVMP/QWP/367182/2025), legally effective from 1 June 2026. It covers solid-phase synthesis, liquid-phase synthesis and fragment condensation; manufacturing process control and characterisation; specifications; conjugation; comparability; sterilisation; and immunogenicity considerations. It sits alongside, rather than replacing, the ICH quality guidelines on impurities and specifications (Q3A, Q6A, M7). Its existence is itself informative: peptides had been governed by a patchwork of small-molecule and biologics guidance, and the regulator concluded that the patchwork was no longer sufficient for a class this large.

Underneath that sits the European Pharmacopoeia, maintained by the EDQM in Strasbourg, whose technical guide for the elaboration of monographs on synthetic peptides and recombinant DNA proteins sets out how an individual peptide monograph is constructed — identity tests, related-substances limits, assay methods, the analytical basis for each.

The practical translation for anyone reading a certificate of analysis is blunt, and it is the same point made at length in how to read a peptide COA: a chromatographic purity figure is an area-percentage of what eluted, not a statement of how much of the powder is peptide. Counterion, residual water and residual solvent are all real mass. European monograph practice separates those questions deliberately, because conflating them is the oldest way to make a number look better than it is. Identity by mass spectrometry and purity by HPLC answer two different questions, and a serious specification asks both.

Where the material is actually made

Europe is also, in unglamorous terms, where a great deal of the world’s peptide is physically produced. Bachem, founded in Switzerland and headquartered in Bubendorf, is among the largest contract manufacturers in the field and has been expanding production across multiple sites; PolyPeptide operates a similar multi-site European footprint. The driver is GLP-1 demand, which has pulled forward capacity investment across the sector on a scale the research-peptide market never would have.

That build-out has a second-order effect worth understanding: it raises the analytical baseline. Facilities built to supply regulated GLP-1 programmes operate to specifications, documentation and impurity controls that did not previously exist at that scale, and the methods developed there propagate outward through the supply chain.

Anti-doping status

Both compounds discussed here are prohibited at all times for athletes under anti-doping rules. TB-500 and thymosin β4 are treated under growth factors and growth factor modulators as non-approved, non-specified substances. BPC-157 is likewise handled as a non-approved substance, and has been the basis of multi-year sanctions — anti-doping laboratory reporting cites a Canadian athlete who received a four-year sanction for BPC-157 and TB-500 together.

The category itself is the point. “Non-approved substance” is not a judgement about the pharmacology; it is a statement that no regulator anywhere has authorised the substance for human use, which is precisely the status both compounds hold in Europe.

What this literature does not establish

A guide that only relays the positive findings of a research programme is marketing. The European record on these two compounds has specific, nameable gaps.

• It does not establish efficacy in humans for either compound. For BPC-157, the human record is one small unpublished phase 1/2 study. For thymosin β4, the most substantial European trial publication describes a protocol in progress, not results.
• It does not establish that TB-500 behaves like thymosin β4. The fragment and the 43-residue parent are different chemical entities, and the European clinical work used the parent.
• It does not establish a human safety profile. Absence of reported adverse events in small, largely preclinical work is not the same as characterised safety, and neither compound has been through the pharmacovigilance machinery that generates that characterisation.
• Concentration of a literature in one institution is a real limitation. This is not an accusation; it is how evidence quality is assessed everywhere. Independent replication at scale is the missing element.
• A salt form is not a new molecule. Marketing that presents an arginine salt of BPC-157 as an improved compound is describing a counterion, not a distinct entity with its own evidence base.

None of this makes the underlying science uninteresting. The gastric-stability finding is a legitimate and unusual result, and the Zagreb group’s persistence over three decades produced a body of work that independent researchers have found worth examining. But a research buyer’s question is narrower than a scientist’s: what has actually been demonstrated, in what model, by whom, and how many times? Answered honestly for these two compounds, the reply is “a great deal in rodents, very little in people, and mostly from one place.”

Frequently asked questions

Where was BPC-157 discovered?

BPC-157 was characterized by a research group at the University of Zagreb School of Medicine in Croatia, led by Predrag Sikirić, beginning in the early 1990s. It is described in that literature as a partial sequence of a protein found in human gastric juice, which is where the “body protection compound” name comes from.

Is BPC-157 approved anywhere in Europe?

No. There is no European Medicines Agency marketing authorisation for BPC-157, and no national approval in an EU member state. The published human record consists of a small early-2000s phase 1/2 study run by the Croatian pharmaceutical company Pliva that was never fully published, and no phase 3 programme followed.

Was thymosin beta-4 ever studied in a European clinical trial?

Yes. A double-blind, placebo-controlled, dose-escalation study of topical thymosin beta-4 in venous ulcers ran across ten sites — five in Italy and five in Poland — with a planned enrolment of 72 patients over 84 days of treatment. It was described by Guarnera, De Rosa and Camerini in the Annals of the New York Academy of Sciences in 2007.

Is TB-500 the same molecule as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue peptide. TB-500 as sold in the research market is a short synthetic fragment associated with the actin-binding region of that parent molecule. Trials described as thymosin beta-4 studies used the full-length peptide, so their findings do not transfer automatically to the fragment.

What does the EMA synthetic peptides guideline cover?

EMA/CHMP/CVMP/QWP/367182/2025, adopted on 9 December 2025 and legally effective from 1 June 2026, sets out expectations for solid-phase synthesis, liquid-phase synthesis and fragment condensation, along with process control, characterisation, specifications and impurity handling for synthetic peptides. It supplements rather than replaces the existing ICH quality guidelines.

Are BPC-157 and TB-500 prohibited in sport?

Both are prohibited at all times for athletes under anti-doping rules. TB-500 and thymosin beta-4 fall under growth factors and are treated as non-approved substances, and BPC-157 has been the basis of multi-year sanctions as a non-approved substance.

References

References were verified against the retrieved source at the time of writing. Where a citation describes a study protocol rather than results, the text says so explicitly.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes research history, published study designs and regulatory frameworks in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.